This clinical study is looking for adults aged 18 years and over who have received a diagnosis of myelodysplastic syndromes (MDS) with anemia. The investigational study drug may help prevent the need for repeated blood transfusions.
The purpose of the study is to compare the effectiveness of a study drug versus a standard of care therapy. People will be evaluated to determine their eligibility for the study. Each eligible person will receive either the study drug or the standard of care therapy, as well as study-related medical examinations and laboratory tests at no cost.
About MDS and anemia
MDS are rare blood cancers in which the blood cells in the bone marrow do not develop and therefore do not become healthy red blood cells, white blood cells or platelets – all the vital components of blood.Not being able to develop healthy red blood cells causes anemia, which is common with MDS. Anemia has many of the same symptoms as MDS and causes even greater fatigue.
It can be exhausting to live with a condition that gives you the impression of being limited in your activities.If you are ’re taking care of a loved one living with this condition, that can be just as tiring. However, research is underway to evaluate an investigational study drug and determine whether it can help alleviate the symptoms of anemia and better manage your MDS. You may be able to participate in this study.
Learn more about study participation
Study participation lasts approximately six years (and may be shorter or longer for some patients). This includes:
A screening period of approximately 35 days,
an initial treatment period of 24 weeks (which can be extended if certain criteria are met and if you continue to benefit from treatment), and
a follow-up period where you will be contacted approximately every 12 weeks to ask how you are doing.
The study drug used in the COMMANDS Trial is a protein that aims to help increase the production of red blood cells in the bone marrow. The study drug will be administered by subcutaneous injection every three weeks during the treatment period.
We recognize the importance of protecting the confidentiality of information related to all people with whom we interact, and we are fully committed to protecting it.